Apparently this is a competition, with the winner receiving 3000 rupees ($40). Seems like a great idea!
The article:
#Let's see, what Scientific Research Landscape on Ivermectin as Prophylaxis for COVID-19 is all about?
The entire world is desperately trying to invent a new drug or repurpose an old one. Intelligence on all such treatments and vaccines is the key to drug discovery for this deadly virus. While vaccines are going to take 12-18 months to come, the best bet that we have to save the world is to find an existing drug that has proven safety profile and found effective in treating COVID-19 patients. Although there are multiple patented and off-patent drugs that being repurposed for COVID-19, specifically one small molecule Ivermectin has shown some promising results in countries Peru and Bangladesh. However, information on this drug is not readily available as of now.
In light of this, we are launching this mini-research hackathon to invite all the innovation catalysts to help us collate existing intelligence on this drug and its combination. Our objective is to help the government kick-start a trial with this drug as India can’t afford to wait for 6-9 months for a vaccine and let the situation worse. We feel it can save a huge cost for our country as it’s an off-patent drug and has many generic versions currently available in the market.
Why Ivermectine?
Australian universities (Monash University & Peter Doherty Institute) identified the possibility of Ivermectin treating COVID-19 in a lab setting in a cell culture within 48 hours. Critics declared this was done with larger doses in vitro not duplicative in human clinical trials. However, the work from the path-breaking scientists in Australia planted the seed of scientific curiosity in researchers around the world. Hence, now Ivermectin proof-of-concept-based human clinical trials are now occurring in the following:
* University of Tanta, Egypt
* Mansoura University, Egypt
* University of Baghdad, Iraq
* General Directorate of Medical City, Iraq
* University of Kentucky, USA
* Johns Hopkins University, USA
* Clinica Universisad de Navarra, Spain
* Combined Military Hospital Lahore, Pakistan
* Max Super Specialty Hospital, Saket, India
* Laboratorio Elea Phoenix S.A., Argentina
* Jose Manuel Arreola Guerra
* Aguascalientes, Mexico (physician)
* Bangladesh Medical College
Based on our research and interviews, there is a growing movement around the world to at least consider experimenting with Ivermectin- especially in some developing economies but also in the developed world. Why? It has a well-established safety profile (it has been in use for decades), it is widely available, and it is economical. If it can be shown that it can fight off COVID-19 as well as if not better than Remdesivir (which probably will cost north of INR 100,000 for the full treatment), then why wouldn’t it be embraced? Of course, evidence from randomized controlled trials is a must and that isn’t available yet, hence the human faith element that can be dangerous.
#Research Focus:
We need the following intelligence around Ivermectine and any combination:
1. Safety profile intelligence along with any Adverse Event recorded in history
1. Past clinical trial records involving Ivermectine and its combinations
1. Record of brand names under which Ivermectine is sold in India (price will be a bonus)
1. Bioavailability (BA) and Bioequivalence (BE) Intelligence
1. Pharmacokinetics (PK) and pharmacodynamics (PD) intelligence
1. Any news and scientific publication providing strong evidence of the pros and cons of Ivermectine as Prophylactics (please paste the relevant sections in the report)
1. Any dossier submitted to the regulatory authority in India or USA will be awesome
The Research Focus lists the most important elements your submission needs to match. The Review team will look for these elements when they review and rank your submissions. To facilitate the review of your submission, you will be asked to copy-paste specific sections of the text that correspond to the elements of the Research Requirements.
[-] TrumpLyftAlles | 1 points | Jun 17 2020 11:18:07
Apparently this is a competition, with the winner receiving 3000 rupees ($40). Seems like a great idea!
The article:
#Let's see, what Scientific Research Landscape on Ivermectin as Prophylaxis for COVID-19 is all about?
The entire world is desperately trying to invent a new drug or repurpose an old one. Intelligence on all such treatments and vaccines is the key to drug discovery for this deadly virus. While vaccines are going to take 12-18 months to come, the best bet that we have to save the world is to find an existing drug that has proven safety profile and found effective in treating COVID-19 patients. Although there are multiple patented and off-patent drugs that being repurposed for COVID-19, specifically one small molecule Ivermectin has shown some promising results in countries Peru and Bangladesh. However, information on this drug is not readily available as of now.
In light of this, we are launching this mini-research hackathon to invite all the innovation catalysts to help us collate existing intelligence on this drug and its combination. Our objective is to help the government kick-start a trial with this drug as India can’t afford to wait for 6-9 months for a vaccine and let the situation worse. We feel it can save a huge cost for our country as it’s an off-patent drug and has many generic versions currently available in the market.
Why Ivermectine?
Australian universities (Monash University & Peter Doherty Institute) identified the possibility of Ivermectin treating COVID-19 in a lab setting in a cell culture within 48 hours. Critics declared this was done with larger doses in vitro not duplicative in human clinical trials. However, the work from the path-breaking scientists in Australia planted the seed of scientific curiosity in researchers around the world. Hence, now Ivermectin proof-of-concept-based human clinical trials are now occurring in the following:
* University of Tanta, Egypt * Mansoura University, Egypt * University of Baghdad, Iraq * General Directorate of Medical City, Iraq * University of Kentucky, USA * Johns Hopkins University, USA * Clinica Universisad de Navarra, Spain * Combined Military Hospital Lahore, Pakistan * Max Super Specialty Hospital, Saket, India * Laboratorio Elea Phoenix S.A., Argentina * Jose Manuel Arreola Guerra * Aguascalientes, Mexico (physician) * Bangladesh Medical College
Based on our research and interviews, there is a growing movement around the world to at least consider experimenting with Ivermectin- especially in some developing economies but also in the developed world. Why? It has a well-established safety profile (it has been in use for decades), it is widely available, and it is economical. If it can be shown that it can fight off COVID-19 as well as if not better than Remdesivir (which probably will cost north of INR 100,000 for the full treatment), then why wouldn’t it be embraced? Of course, evidence from randomized controlled trials is a must and that isn’t available yet, hence the human faith element that can be dangerous.
#Research Focus:
We need the following intelligence around Ivermectine and any combination:
1. Safety profile intelligence along with any Adverse Event recorded in history 1. Past clinical trial records involving Ivermectine and its combinations 1. Record of brand names under which Ivermectine is sold in India (price will be a bonus) 1. Bioavailability (BA) and Bioequivalence (BE) Intelligence 1. Pharmacokinetics (PK) and pharmacodynamics (PD) intelligence 1. Any news and scientific publication providing strong evidence of the pros and cons of Ivermectine as Prophylactics (please paste the relevant sections in the report) 1. Any dossier submitted to the regulatory authority in India or USA will be awesome
The Research Focus lists the most important elements your submission needs to match. The Review team will look for these elements when they review and rank your submissions. To facilitate the review of your submission, you will be asked to copy-paste specific sections of the text that correspond to the elements of the Research Requirements.
permalink